Literature DB >> 34655374

Luteolin Suppresses Microglia Neuroinflammatory Responses and Relieves Inflammation-Induced Cognitive Impairments.

Wei Zhou1, Mengmeng Hu1, Jingrong Hu1, Zhiyun Du1, Qing Su2, Zhangmin Xiang3.   

Abstract

Microglia-mediated neuroinflammation in response to injurious self and non-self-stimuli exerts detrimental effects on neurons, which may lead to cognitive impairment. Luteolin, a typical kind of natural flavonoid in honeysuckle, chrysanthemum, and Herba Schizonepetae, is widely recognized to be anti-inflammatory and antioxidant against peripheral inflammation. However, its protective effect against inflammation-induced cognitive impairment is currently unknown. In this paper, we investigated the relief potential of luteolin against lipopolysaccharide (LPS)-induced cognitive impairment and neuroinflammation and its possible anti-inflammatory mechanisms in lipopolysaccharide-stimulated BV2 microglia cells. In this study, luteolin ameliorated LPS-induced cognitive impairments, indicated by behavioral performance of neuroinflammatory model mice in Morris water maze tests. Protein analyses and histological examination also revealed protective effect of luteolin against neuronal damage, through inhibiting overproduction of inflammatory cytokines in both hippocampus and cortex of mice. We also observed luteolin in vitro significantly suppressed the levels of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-1 β (IL-1β), and inflammatory mediators like nitric oxide. Taken together, these results demonstrated luteolin was effective in alleviating cognitive impairment and limited neuronal damage via inhibiting the release of inflammatory mediators, suggesting luteolin is potential for further therapeutic research of neuroinflammation-related neurodegenerative diseases.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cognitive impairment; Inflammatory cytokines; Lipopolysaccharide; Luteolin; Neuroinflammation

Mesh:

Substances:

Year:  2021        PMID: 34655374     DOI: 10.1007/s12640-021-00426-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  25 in total

1.  Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

Authors:  Xiaohua Deng; Meili Li; Weiming Ai; Lixin He; Dahua Lu; Peter R Patrylo; Huaibin Cai; Xuegang Luo; Zhiyuan Li; Xiaoxin Yan
Journal:  Adv Alzheimer Dis       Date:  2014-06

Review 2.  Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation.

Authors:  Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  A network pharmacology strategy to investigate the anti-inflammatory mechanism of luteolin combined with in vitro transcriptomics and proteomics.

Authors:  Xiu-Fang Huang; Jia-Lin Zhang; Dan-Ping Huang; Ai-Si Huang; Hui-Ting Huang; Qiong Liu; Xiao-Hong Liu; Hui-Li Liao
Journal:  Int Immunopharmacol       Date:  2020-06-24       Impact factor: 4.932

4.  Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type.

Authors:  H Javed; M M Khan; A Ahmad; K Vaibhav; M E Ahmad; A Khan; M Ashafaq; F Islam; M S Siddiqui; M M Safhi; F Islam
Journal:  Neuroscience       Date:  2012-03-06       Impact factor: 3.590

5.  Luteolin suppresses IL-31 production in IL-33-stimulated mast cells through MAPK and NF-κB signaling pathways.

Authors:  Denis Nchang Che; Jae Young Shin; Hyun Ju Kang; Byoung Ok Cho; Young-Soo Kim; Seon Il Jang
Journal:  Int Immunopharmacol       Date:  2020-03-18       Impact factor: 4.932

6.  Streptozotocin Induces Mild Cognitive Impairment at Appropriate Doses in Mice as Determined by Long-Term Potentiation and the Morris Water Maze.

Authors:  Dong Li; Yan Huang; Bin Cheng; Jie Su; Wen-Xia Zhou; Yong-Xiang Zhang
Journal:  J Alzheimers Dis       Date:  2016-07-27       Impact factor: 4.472

Review 7.  Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma.

Authors:  Duraisamy Kempuraj; Ramasamy Thangavel; Deepak D Kempuraj; Mohammad Ejaz Ahmed; Govindhasamy Pushpavathi Selvakumar; Sudhanshu P Raikwar; Smita A Zaheer; Shankar S Iyer; Raghav Govindarajan; Premkumar Nattanmai Chandrasekaran; Asgar Zaheer
Journal:  Biofactors       Date:  2020-10-24       Impact factor: 6.113

8.  Validation of cyclooxygenase-2 as a direct anti-inflammatory target of 4-O-methylhonokiol in zymosan-induced animal models.

Authors:  Hyung Sook Kim; Hwa Sun Ryu; Ji Sung Kim; Yong Guk Kim; Hong Kyung Lee; Jae Kyung Jung; Young Shin Kwak; Kiho Lee; Seung Yong Seo; Jieun Yun; Jong Soon Kang; Jin Tae Hong; Youngsoo Kim; Sang-Bae Han
Journal:  Arch Pharm Res       Date:  2014-07-31       Impact factor: 4.946

9.  Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.

Authors:  Niloufar Ansari; Fariba Khodagholi
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 10.  Microglia in neurodegeneration.

Authors:  Suzanne Hickman; Saef Izzy; Pritha Sen; Liza Morsett; Joseph El Khoury
Journal:  Nat Neurosci       Date:  2018-09-26       Impact factor: 24.884

View more
  2 in total

1.  Effect of Yakae-Prajamduen-Jamod Traditional Thai Remedy on Cognitive Impairment in an Ovariectomized Mouse Model and Its Mechanism of Action.

Authors:  Supawadee Daodee; Orawan Monthakantirat; Ariyawan Tantipongpiradet; Juthamart Maneenet; Yutthana Chotritthirong; Chantana Boonyarat; Charinya Khamphukdee; Pakakrong Kwankhao; Supaporn Pitiporn; Suresh Awale; Kinzo Matsumoto; Yaowared Chulikhit
Journal:  Molecules       Date:  2022-07-05       Impact factor: 4.927

2.  Luteolin Potentially Treating Prostate Cancer and COVID-19 Analyzed by the Bioinformatics Approach: Clinical Findings and Drug Targets.

Authors:  Yu Ye; Ziyan Huang; Manying Chen; Yongfeng Mo; Zengnan Mo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-01       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.